SCHEMBL7796008

SCHEMBL7796008

O=C(CN1C(=O)CCC1=O)OO

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 6/20 0.40
ALOX12 P18054 1/20 0.40
HPGD P15428 2/20 0.39
TSHR P16473 2/20 0.39
LMNA P02545 3/20 0.38
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
KDM4E B2RXH2 3/20 0.36
GFER P55789 2/20 0.36
HSD17B10 Q99714 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
G6PD P11413 1/20 0.36
HTT P42858 1/20 0.36
CDK2 P24941 1/20 0.35
GSK3A P49840 2/20 0.34
GSK3B P49841 2/20 0.34
GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2002948 0.80 ALDH1A1 (0.42) RAB9ASMN1; SMN2ALDH1A1ALOX12HPGD
SCHEMBL668458 0.80 RAB9A (0.40) RAB9ASMN1; SMN2ALDH1A1ALOX12HPGD
SCHEMBL2754581 0.80 ALDH1A1 (0.49) RAB9ASMN1; SMN2ALDH1A1ALOX12HPGD
SCHEMBL13895524 0.78 RAB9A (0.39) RAB9ASMN1; SMN2ALDH1A1ALOX12HPGD
SCHEMBL7802043 0.78 SMN1; SMN2 (0.40) SMN1; SMN2ALDH1A1HPGDMEN1KMT2A
SCHEMBL18825277 0.77 GSK3A (0.61) RAB9AALDH1A1LMNAMEN1KMT2A
SCHEMBL13819868 0.77 CYP19A1 (0.38) RAB9ASMN1; SMN2ALDH1A1ALOX12HPGD
SCHEMBL4671579 0.75 ALDH1A1 (0.39) RAB9ASMN1; SMN2ALDH1A1ALOX12HPGD
SCHEMBL9532098 0.75 PLA2G10 (0.40) RAB9ASMN1; SMN2ALDH1A1HPGDTSHR
SCHEMBL22147439 0.75 ALDH1A1 (0.49) RAB9ASMN1; SMN2ALDH1A1HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0366041-B2 Imido-percarboxylic acids AUSIMONT SPA (IT) 2001-09-12 EP claimed
EP-0366041-B1 Imido-percarboxylic acids AUSIMONT SPA (IT) 1998-08-05 EP claimed
US-5536434-A BLEACHES AUSIMONT S.P.A. (IT) 1996-07-16 US claimed
US-20100189675-A1 COSMETIC USE OF AN IMIDOPERCARBOXYLIC ACID DERIVATIVE AS DESQUAMATING AGENT L'OREAL (FR) 2010-07-29 US disclosed
US-20090275630-A1 COSMETIC COMPOSITION COMPRISING AN IMIDOPERCARBOXYLIC ACID DERIVATIVE AND A N-ACYLATED AMINO ACID ESTER L'OREAL (FR) 2009-11-05 US disclosed
US-20070037990-A1 Method of producing an organic compound comprising at least one oxygenated functional group SOLVAY S.A. (BE) 2007-02-15 US disclosed
EP-0366041-B2 Imido-percarboxylic acids AUSIMONT SPA (IT) 2001-09-12 EP disclosed
EP-0366041-B1 Imido-percarboxylic acids AUSIMONT SPA (IT) 1998-08-05 EP disclosed
US-5536434-A BLEACHES AUSIMONT S.P.A. (IT) 1996-07-16 US disclosed
EP-0366041-A2 Imido-percarboxylic acids AUSIMONT S.r.l. (IT) 1990-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100189675-A1 COSMETIC USE OF AN IMIDOPERCARBOXYLIC ACID DERIVATIVE AS DESQUAMATING AGENT NISCH, CUTA, DDC RAB9A 3655/4885SMN1; SMN2 3767/4885ALDH1A1 1251/4885
US-20070037990-A1 Method of producing an organic compound comprising at least one oxygenated functional group OGDH, OSTC, AOX1 RAB9A 4728/4885SMN1; SMN2 3226/4885ALDH1A1 371/4885
US-20090275630-A1 COSMETIC COMPOSITION COMPRISING AN IMIDOPERCARBOXYLIC ACID DERIVATIVE AND A N-ACYLATED AMINO ACID ESTER DDC, ALAD, AADAC RAB9A 2648/4885SMN1; SMN2 3579/4885ALDH1A1 407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.